Cooley Rx series
Life Sciences Litigation: Preparing for Successful Hatch-Waxman Litigation
Event summary
Cooley Rx is a virtual series focused on the life sciences and healthcare sectors. Join us as we discuss the top issues and trends in these industries – and provide decision-makers with information they can use to strengthen their organizations.
Obtaining favorable results in Hatch-Waxman litigation is critical for branded drug companies. Cooley life sciences litigation partners Chad Shear and Geoff Biegler discussed strategies for branded companies to best position themselves for success in Hatch-Waxman litigation. Leveraging 40+ years of combined experience in abbreviated new drug application (ANDA) cases. Chad and Geoff walked through when one should prepare for Hatch-Waxman litigation, what steps one should take and how to avoid common pitfalls.
For more information, please email Megan Senerchia.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.